Pinebridge Investments L.P. Buys 10,055 Shares of Bruker Co. (NASDAQ:BRKR)

Pinebridge Investments L.P. raised its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 42.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 33,619 shares of the medical research company's stock after purchasing an additional 10,055 shares during the quarter. Pinebridge Investments L.P.'s holdings in Bruker were worth $1,971,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Eagle Bay Advisors LLC raised its stake in Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after buying an additional 674 shares during the period. UMB Bank n.a. raised its stake in Bruker by 37.5% in the 4th quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock valued at $53,000 after acquiring an additional 248 shares during the period. GAMMA Investing LLC lifted its holdings in Bruker by 47.5% during the 4th quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after purchasing an additional 412 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Bruker by 18.2% during the fourth quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock worth $75,000 after purchasing an additional 196 shares during the period. Finally, EverSource Wealth Advisors LLC raised its position in shares of Bruker by 41.5% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock valued at $78,000 after purchasing an additional 390 shares during the period. Institutional investors and hedge funds own 79.52% of the company's stock.

Bruker Stock Up 0.3 %

NASDAQ BRKR opened at $39.07 on Monday. The business has a fifty day moving average price of $43.22 and a two-hundred day moving average price of $52.62. The stock has a market capitalization of $5.92 billion, a PE ratio of 51.41, a PEG ratio of 2.16 and a beta of 1.18. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $82.04. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. Equities analysts expect that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Monday, March 17th were paid a dividend of $0.05 per share. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.51%. Bruker's payout ratio is presently 26.32%.

Analyst Ratings Changes

A number of research analysts recently commented on BRKR shares. Wells Fargo & Company decreased their price target on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating on the stock in a research note on Thursday, April 17th. Citigroup lowered their target price on Bruker from $75.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Guggenheim restated a "buy" rating on shares of Bruker in a research note on Monday, February 24th. Barclays lowered their price objective on Bruker from $60.00 to $50.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, Stifel Nicolaus reduced their target price on shares of Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a research report on Friday, February 14th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $65.00.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Want to see what other hedge funds are holding BRKR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bruker Co. (NASDAQ:BRKR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.